113 related articles for article (PubMed ID: 2917019)
41. Human ovarian cancers specifically bind daunorubicin-OC-125 conjugate: an immunofluorescence study.
Dezsö B; Török I; Rosik LO; Sweet F
Gynecol Oncol; 1990 Oct; 39(1):60-4. PubMed ID: 2227573
[TBL] [Abstract][Full Text] [Related]
42. Experimental immunotherapy of human breast carcinomas implanted in nude mice with a mixture of monoclonal antibodies against human milk fat globule components.
Ceriani RL; Blank EW; Peterson JA
Cancer Res; 1987 Jan; 47(2):532-40. PubMed ID: 3791239
[TBL] [Abstract][Full Text] [Related]
43. Identification of a family of high molecular weight tumor-associated glycoproteins.
Abe M; Kufe DW
J Immunol; 1987 Jul; 139(1):257-61. PubMed ID: 2438351
[TBL] [Abstract][Full Text] [Related]
44. Multidrug resistance in cultured human leukemia and lymphoma cell lines detected by a monoclonal antibody, MRK16.
Ishida Y; Ohtsu T; Hamada H; Sugimoto Y; Tobinai K; Minato K; Tsuruo T; Shimoyama M
Jpn J Cancer Res; 1989 Oct; 80(10):1006-13. PubMed ID: 2575608
[TBL] [Abstract][Full Text] [Related]
45. Purification and biochemical characterisation of a novel breast carcinoma associated mucin-like glycoprotein defined by antibody 3E1.2.
Stacker SA; Tjandra JJ; Xing PX; Walker ID; Thompson CH; McKenzie IF
Br J Cancer; 1989 Apr; 59(4):544-53. PubMed ID: 2469454
[TBL] [Abstract][Full Text] [Related]
46. Characterization and distribution in normal and tumoral human tissues of breast cancer-associated antigen defined by monoclonal antibody 7B10.
Pancino GF; Le Doussal V; Mortada MH; Berthon P; Osinaga E; Calvo F; Roseto A
Cancer Res; 1989 Dec; 49(24 Pt 1):7078-85. PubMed ID: 2555058
[TBL] [Abstract][Full Text] [Related]
47. Characterization of monoclonal antibody 436 recognizing the Arg-Pro-Ala-Pro sequence of the polymorphic epithelial mucin (PEM) protein core in breast carcinoma cells.
Nuti M; Turchi V; Rughetti A; Viacava P; Masci AM; Castagna M; Frati L
Int J Biol Markers; 1992; 7(2):71-9. PubMed ID: 1378874
[TBL] [Abstract][Full Text] [Related]
48. Cytotoxicity of glucose oxidase conjugated with antibodies to target cells: killing efficiency depends on the conjugate internalization.
Muzykantov VR; Trubetskaya OV; Puchnina EA; Sakharov DV; Domogatsky SP
Biochim Biophys Acta; 1990 Jun; 1053(1):27-31. PubMed ID: 2364115
[TBL] [Abstract][Full Text] [Related]
49. Coupling a preactivated daunorubicin derivative to antibody. A new approach.
Pagé M; Thibeault D; Noël C; Dumas L
Anticancer Res; 1990; 10(2A):353-7. PubMed ID: 2346308
[TBL] [Abstract][Full Text] [Related]
50. Immunochemotherapy of a murine thymoma with the use of idarubicin monoclonal antibody conjugates.
Pietersz GA; Smyth MJ; McKenzie IF
Cancer Res; 1988 Feb; 48(4):926-31. PubMed ID: 3422182
[TBL] [Abstract][Full Text] [Related]
51. Efficacy and selectivity of monoclonal-antibody-targeted drugs and free methotrexate in fluorescence-labelled mixed tumour-cell monolayer cultures and multicellular spheroids.
Embleton MJ; Charleston A; Affleck K
Int J Cancer; 1991 Oct; 49(4):566-72. PubMed ID: 1917158
[TBL] [Abstract][Full Text] [Related]
52. A Mucin1 C-terminal Subunit-directed Monoclonal Antibody Targets Overexpressed Mucin1 in Breast Cancer.
Wu G; Kim D; Kim JN; Park S; Maharjan S; Koh H; Moon K; Lee Y; Kwon HJ
Theranostics; 2018; 8(1):78-91. PubMed ID: 29290794
[No Abstract] [Full Text] [Related]
53. Kinetics of daunorubicin transport by P-glycoprotein of intact cancer cells.
Spoelstra EC; Westerhoff HV; Dekker H; Lankelma J
Eur J Biochem; 1992 Jul; 207(2):567-79. PubMed ID: 1353020
[TBL] [Abstract][Full Text] [Related]
54. Nature of linkage and mode of action of methotrexate conjugated with antitumor antibodies: implications for future preparation of conjugates.
Endo N; Takeda Y; Umemoto N; Kishida K; Watanabe K; Saito M; Kato Y; Hara T
Cancer Res; 1988 Jun; 48(12):3330-5. PubMed ID: 3259466
[TBL] [Abstract][Full Text] [Related]
55. A gelonin-containing immunotoxin directed against human breast carcinoma.
Rosenblum MG; Zuckerman JE; Marks JW; Rotbein J; Allen WR
Mol Biother; 1992 Sep; 4(3):122-9. PubMed ID: 1445665
[TBL] [Abstract][Full Text] [Related]
56. BR96 conjugates of highly potent anthracyclines.
King HD; Staab AJ; Pham-Kaplita K; Yurgaitis D; Firestone RA; Lasch SJ; Trail PA
Bioorg Med Chem Lett; 2003 Jul; 13(13):2119-22. PubMed ID: 12798317
[TBL] [Abstract][Full Text] [Related]
57. A monoclonal antibody-beta-glucuronidase conjugate as activator of the prodrug epirubicin-glucuronide for specific treatment of cancer.
Haisma HJ; Boven E; van Muijen M; de Jong J; van der Vijgh WJ; Pinedo HM
Br J Cancer; 1992 Sep; 66(3):474-8. PubMed ID: 1520585
[TBL] [Abstract][Full Text] [Related]
58. Long-lasting complete inhibition of human solid tumors in SCID mice by targeting endothelial cells of tumor vasculature with antihuman endoglin immunotoxin.
Seon BK; Matsuno F; Haruta Y; Kondo M; Barcos M
Clin Cancer Res; 1997 Jul; 3(7):1031-44. PubMed ID: 9815781
[TBL] [Abstract][Full Text] [Related]
59. Antigen-specific activity of carcinoma-reactive BR64-doxorubicin conjugates evaluated in vitro and in human tumor xenograft models.
Trail PA; Willner D; Lasch SJ; Henderson AJ; Greenfield RS; King D; Zoeckler ME; Braslawsky GR
Cancer Res; 1992 Oct; 52(20):5693-700. PubMed ID: 1382845
[TBL] [Abstract][Full Text] [Related]
60. [Activity of toremifene plus mitomycin, vindesin and cisplatin regimen in unresectable non-small cell lung cancer].
Zhou CC; Zhang J; Zheng D; Lu MJ; Lu B; Xu JF
Zhonghua Jie He He Hu Xi Za Zhi; 2004 Aug; 27(8):546-8. PubMed ID: 15388005
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
